| Ident. | Authors (with country if any) | Title |
|---|
| 000F47 |
F. Tubach [France] ; P. Ravaud [France] ; E. Martin-Mola [Espagne] ; H. Awada [Liban] ; N. Bellamy [Australie] ; C. Bombardier [Canada] ; D. T. Felson [États-Unis] ; N. Hajjaj-Hassouni [Maroc] ; M. Hochberg [États-Unis] ; I. Logeart [France] ; M. Matucci-Cerinic [Italie] ; M. Van De Laar [Pays-Bas] ; D. Van Der Heijde [Pays-Bas] ; M. Dougados [France] | Minimum Clinically Important Improvement and Patient Acceptable Symptom State in Pain and Function in Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Back Pain, Hand Osteoarthritis, and Hip and Knee Osteoarthritis: Results From a Prospective Multinational Study |
| 004289 |
F. Tubach [France] ; G. Baron [France] ; B. Falissard [France] ; I. Logeart [France] ; M. Dougados [France] ; N. Bellamy [Australie] ; P. Ravaud [France] | Using patients' and rheumatologists' opinions to specify a short form of the WOMAC function subscale |
| 004617 |
F. Tubach [France] ; P. Ravaud [France] ; G. Baron [France] ; B. Falissard [France] ; I. Logeart [France] ; N. Bellamy [Australie] ; C. Bombardier [Canada] ; D. Felson [États-Unis] ; M. Hochberg [États-Unis] ; D. Van Der Heijde [Pays-Bas] ; M. Dougados [France] | Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state |
| 004618 |
F. Tubach [France] ; P. Ravaud [France] ; G. Baron [France] ; B. Falissard [France] ; I. Logeart [France] ; N. Bellamy [Australie] ; C. Bombardier [Canada] ; D. Felson [États-Unis] ; M. Hochberg [États-Unis] ; D. Van Der Heijde [Pays-Bas] ; M. Dougados [France] | Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement |
| 006637 |
N. Bellamy [Canada, Royaume-Uni, Pays-Bas, Australie, États-Unis, France] ; J. Kirwan ; M. Boers ; P. Brooks ; V. Strand ; P. Tugwell ; R. Altman ; K. Brandt ; M. Dougados ; M. Lequesne | Recommendations for a core set of outcome measures for future Phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III |
